Top Markets
Coin of the day
Nuformix plc Nuformix plc

Nuformix plc

NFX
Rang in aandelen #20651
Nuformix plc operates in the field of pharmaceutical development for treating... Nuformix plc operates in the field of pharmaceutical development for treating fibrosis and oncology through drug repurposing in the United Kingdom. It offers NXP001, which has completed Phase 1 for use in oncology supportive care. The company is also developing NXP004, a novel form of Olaparib, which is in the IP generation phase for treating oncology; and NXP002 that is in pre-clinical stage for the treatment of idiopathic pulmonary fibrosis. It also has an option agreement with Oxilio Ltd. for NXP001 for oncology indications. Nuformix plc was founded in 2008 and is based in London, the United Kingdom.
Aandeelprijs
$0.00244926
Marktkapitalisatie
$51.67K
Verandering (1 dag)
5.88%
Verandering (1 jaar)
110.15%
Land
GB
Handel Nuformix plc (NFX)

Categorie

Winst voor Nuformix plc (NFX)
Winst in Sep 2025 TTM: $-5.28M
Volgens de meest recente financiële verslagen van Nuformix plc bedraagt de huidige winst van het bedrijf $-5.28M. In 2024 behaalde het bedrijf een winst van $-4.88M, een daling ten opzichte van de winst van 2023, die $-754.56K bedroeg. De weergegeven winst op deze pagina is de winst vóór rente en belastingen, oftewel EBIT.
Winstgeschiedenis van Nuformix plc van 2014 tot 2026
Winst aan het einde van elk jaar
Jaar Winst Wijzigen
2026 (TTM) $-5.28M 494.63%
2025 $-888.01K -81.80%
2024 $-4.88M 546.72%
2023 $-754.56K -54.82%
2022 $-1.67M -11.94%
2021 $-1.90M 64.37%
2020 $-1.15M -51.92%
2019 $-2.40M -12.87%
2018 $-2.75M 220.48%
2017 $-859.40K 70.68%
2016 $-503.51K -206.04%
2014 $474.83K 0.00%
Winst van vergelijkbare bedrijven of concurrenten
Bedrijf Winst Winstverschil Land
$20.46B -387,521.89%
DK
$4.64B -88,033.93%
US
$5.23B -99,160.13%
US
$2.14B -40,584.12%
BE
$1.61B -30,671.66%
AU